Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $411 from $424 and keeps a Hold rating on the shares. The firm said its 2Q report was uneventful on the commercial side as the company delivered a slight topline beat but reiterated guidance. The news on its non-opiod pain drug candidate was not so good as the company announced its VX-993 (more potent Nav1.8 inhibitor) did not show a stat sig benefit versus placebo in a Ph2 arm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals upgraded to Overweight from Equal Weight at Wells Fargo
- Vertex Pharmaceuticals: Strong Growth and Strategic Advances
- Video: Palantir, Axon lead early movers after earnings
- video: Why These Stocks Are Moving Today
- Vertex Pharmaceuticals price target lowered to $490 from $520 at Truist